Predicted protein targets (top 14)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | HDAC3 | O15379 | 3/20 | 0.47 |
| ▸ | HDAC1 | Q13547 | 3/20 | 0.47 |
| ▸ | HDAC2 | Q92769 | 3/20 | 0.47 |
| ▸ | ADORA1 | P30542 | 4/20 | 0.46 |
| ▸ | ADORA2A | P29274 | 3/20 | 0.46 |
| ▸ | ADORA3 | P0DMS8 | 3/20 | 0.46 |
| ▸ | ALDH1A1 | P00352 | 1/20 | 0.46 |
| ▸ | HPGD | P15428 | 1/20 | 0.45 |
| ▸ | NPC1 | O15118 | 1/20 | 0.44 |
| ▸ | RAB9A | P51151 | 1/20 | 0.44 |
| ▸ | CETP | P11597 | 1/20 | 0.44 |
| ▸ | GSK3A | P49840 | 1/20 | 0.43 |
| ▸ | GSK3B | P49841 | 1/20 | 0.43 |
| ▸ | RXFP2 | Q8WXD0 | 1/20 | 0.43 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL22853567 | 1.00 | HDAC3 (0.47) | HDAC3HDAC1HDAC2ADORA1ADORA2A | |
| SCHEMBL20368668 | 0.81 | HDAC3 (0.51) | HDAC3HDAC1HDAC2ADORA1ADORA2A | |
| SCHEMBL22138697 | 0.81 | HDAC3 (0.39) | HDAC3HDAC1HDAC2ALDH1A1NPC1 | |
| SCHEMBL21157773 | 0.81 | HDAC3 (0.44) | HDAC3HDAC1HDAC2ALDH1A1NPC1 | |
| SCHEMBL20368588 | 0.81 | HDAC3 (0.44) | HDAC3HDAC1HDAC2ALDH1A1NPC1 | |
| SCHEMBL22018162 | 0.81 | HDAC3 (0.44) | HDAC3HDAC1HDAC2ALDH1A1NPC1 | |
| SCHEMBL20368587 | 0.81 | HDAC3 (0.44) | HDAC3HDAC1HDAC2ALDH1A1NPC1 | |
| SCHEMBL19059603 | 0.76 | GSK3B (0.55) | HDAC3HDAC1HDAC2ADORA1ADORA2A | |
| SCHEMBL22019115 | 0.75 | HDAC3 (0.49) | HDAC3HDAC1HDAC2ADORA1ADORA2A | |
| SCHEMBL22853620 | 0.75 | HDAC3 (0.46) | HDAC3HDAC1HDAC2ADORA1ADORA2A |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 2 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-9849120-B2 | Thiazolecarboxamides and pyridinecarboxamide compounds useful as Pim kinase inhibitors | INCYTE HOLDINGS CORPORATION (US) | 2017-12-26 | — | — | US | disclosed |
| US-20170182017-A1 | THIAZOLECARBOXAMIDES AND PYRIDINECARBOXAMIDE COMPOUNDS USEFUL AS PIM KINASE INHIBITORS | INCYTE CORPORATION | 2017-06-29 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20170182017-A1 | THIAZOLECARBOXAMIDES AND PYRIDINECARBOXAMIDE COMPOUNDS USEFUL AS PIM KINASE INHIBITORS | PIM2, PIM1, PIM3 | HDAC3 487/4885HDAC1 359/4885HDAC2 532/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.